Table 2 The expected effect on patent value according to pharmaceutical industry related factors
Variable | Definition | Expected effect on Patent value | Date source |
|---|---|---|---|
CRECEIVE | Number of citations received | + | NBER |
OPPOSITION | The occurrence of opposition (1:yes; 0: no) | + | INPADOC |
CLAIMS | Number of claims | + | NBER |
CMADE | Number of citations mode | + | NBER |
BLOCKBUSTER | Blocbuster drug (1:yes; 0: no) | + | PHARMADL |
PORTFOLIO | Number of patents in a patent portfolio | + | FDA |
NDS | New dosing schedule (1:yes; 0: no) | Unknown | FDA |
NI | New indication (1:yes; 0: no) | Unknown | FDA |
NC | New combination (1:yes; 0: no) | + | FDA |
NCE | New chemical entity (1:yes; 0: no) | + | FDA |
NDF | New dosage form (1:yes; 0: no) | + | FDA |
NP | New product (1:yes; 0: no) | + | FDA |
NS | New strength (1:yes; 0: no) | Unknown | FDA |
OD | Orphan drug (1:yes; 0: no) | - | FDA |
PD | Pediatric drug (1:yes; 0: no) | - | FDA |
GYEAR | Grant year | - | NBER |